CD8A and neoplasm: Based on these mechanisms, combined PTT and immunotherapy using immunologic adjuvants can increase tumor immunogenicity and reduce immunosuppression in the TME via immune-checkpoint inhibitors, resulting in an enhancement in the tumor infiltration of cytotoxic CD8+ T-cells and effector memory T-cells.